<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038895</url>
  </required_header>
  <id_info>
    <org_study_id>UNIPV002DIM2009</org_study_id>
    <secondary_id>2009-016481-83</secondary_id>
    <nct_id>NCT01038895</nct_id>
  </id_info>
  <brief_title>Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the extent and trend in time of antiproteinuric
      effect as well as that antihypertensive effect of aliskiren 300 mg / d versus ramipril 10 mg
      daily in hypertensive patients with type 2 diabetes and microalbuminuria. The investigators
      will also evaluate:

        1. Average of 24 hours, as determined by ABPM, systolic and diastolic blood pressure checks
           at various visits

        2. Average daytime, as determined by ABPM, systolic and diastolic blood pressure checks at
           various visits 3. Average night, as determined by ABPM, systolic and diastolic blood
           pressure checks at various visits
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antiproteinuric effect as well as antihypertensive effect of aliskiren 300 mg / daily versus ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average of 24 hours by ABPM, systolic and diastolic blood pressure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daytime, systolic and diastolic blood pressure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average night, systolic and diastolic blood pressure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg/ daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>tablet; 10 mg; od; 3 months</description>
    <arm_group_label>Ramipril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental</intervention_name>
    <description>tablet; 300 mg; od; 3 months</description>
    <arm_group_label>Aliskiren</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  blood pressure &gt; 130/80 &lt;180/105 mmHg at the end of the wash−out

               -  type 2 diabetes mellitus well controlled by medication and / or compliance with
                  diet (HbA1c &lt;7%)

               -  microalbuminuria in the upper range of normal (&gt; 200 &lt;300 mg/24 h)

        Exclusion Criteria:

          -  Pregnancy, lactation or women of childbearing age

          -  Sitting diastolic blood pressure e 105 mmHg or systolic pressure e 180 at the end of
             the period of wash−out

          -  History of hypertensive encephalopathy or cerebrovascular accident within 6 months

          -  Secondary hypertension

          -  Heart Failure

          -  Myocardial infarction within 6 months

          -  Angina pectoris, clinically significant valvular disease or arrhythmia

          -  Alteration indices of liver function or renal

          -  Known hypersensitivity to ACE inhibitors

          -  All other physiological or pathological condition in the opinion of the physician may
             affect the evaluation of the parameters under study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Fogari, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto Fogari, MD</last_name>
    <phone>+39 0382 526217</phone>
    <email>r.fogari@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pavia</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amedeo Mugellini, MD</last_name>
      <phone>+39 0382 526217</phone>
      <email>amedeo.mugellini@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Amedeo Mugellini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>December 23, 2009</last_update_submitted>
  <last_update_submitted_qc>December 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>University of Pavia</name_title>
    <organization>University of Pavia</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>aliskiren</keyword>
  <keyword>ramipril</keyword>
  <keyword>microalbuminuria</keyword>
  <keyword>blood pressure&gt; 130/80 &lt;180/105 mmHg at the end of the wash−out</keyword>
  <keyword>type 2 diabetes mellitus well controlled by medication and / or</keyword>
  <keyword>compliance with diet (HbA1c &lt;7%)</keyword>
  <keyword>Microalbuminuria in the upper range of normal (&gt; 200 &lt;300 mg/24 h)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

